Intellia Therapeutics Inc (NTLA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Intellia Therapeutics Inc (NTLA) has a cash flow conversion efficiency ratio of -0.103x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-69.28 Million) by net assets ($671.39 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Intellia Therapeutics Inc (NTLA) net asset quality to measure how much of total assets are equity-financed.
Intellia Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Intellia Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Intellia Therapeutics Inc cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Intellia Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Intellia Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Innovative Medical Management Co Ltd
SHE:002173
|
-0.007x |
|
EFORT Intelligent Equipment Co Ltd
SHG:688165
|
-0.078x |
|
Jeju Semiconductor Corp
KQ:080220
|
-0.121x |
|
Bank Pan Indonesia Tbk
JK:PNBN
|
0.026x |
|
WAM Capital Ltd
AU:WAM
|
0.063x |
|
Wuxi Chipown Micro-electronics Ltd
SHG:688508
|
-0.010x |
|
Implenia AG
SW:IMPN
|
0.364x |
|
Shandong Weigao Orthopaedic Device Co. Ltd. A
SHG:688161
|
N/A |
Annual Cash Flow Conversion Efficiency for Intellia Therapeutics Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Intellia Therapeutics Inc from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see Intellia Therapeutics Inc (NTLA) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $671.39 Million | $-348.88 Million | -0.520x | -29.87% |
| 2024-12-31 | $871.96 Million | $-348.88 Million | -0.400x | -6.62% |
| 2023-12-31 | $1.05 Billion | $-394.09 Million | -0.375x | -39.12% |
| 2022-12-31 | $1.24 Billion | $-333.29 Million | -0.270x | -24.69% |
| 2021-12-31 | $1.04 Billion | $-225.03 Million | -0.216x | -128.44% |
| 2020-12-31 | $527.07 Million | $-49.91 Million | -0.095x | +75.25% |
| 2019-12-31 | $269.88 Million | $-103.24 Million | -0.383x | -73.56% |
| 2018-12-31 | $277.92 Million | $-61.26 Million | -0.220x | -1.50% |
| 2017-12-31 | $300.60 Million | $-65.28 Million | -0.217x | -226.19% |
| 2016-12-31 | $209.84 Million | $36.11 Million | 0.172x | +757.44% |
| 2015-12-31 | $67.36 Million | $-1.76 Million | -0.026x | +94.31% |
| 2014-12-31 | $7.57 Million | $-3.48 Million | -0.460x | -- |
About Intellia Therapeutics Inc
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. The company has license and collaboration agree… Read more